Examkin

Soru

Zorluk: ZorPharmacologic Interventions

A 58-year-old man is evaluated in the hospital for a 5-day history of fever, nonproductive cough, and right-sided pleuritic chest pain. He underwent a deceased-donor renal transplantation eight months ago and is maintained on a daily immunosuppressive regimen of tacrolimus, mycophenolate mofetil, and low-dose prednisone. Vital signs are temperature 38.6∘C38.6^\circ\text{C} (101.5∘F101.5^\circ\text{F}), pulse 108/min108/\text{min}, respirations 20/min20/\text{min}, and blood pressure 138/82 mm Hg138/82\text{ mm Hg}. Chest computed tomography reveals a dense right upper lobe nodule with a surrounding halo of ground-glass attenuation. Serum galactomannan assay is strongly positive, and bronchoscopy with bronchoalveolar lavage confirms the diagnosis of invasive pulmonary aspergillosis. The medical team decides to initiate the standard first-line targeted intravenous antifungal therapy for this condition. Which of the following concurrent pharmacologic interventions is most appropriate for this patient?

  1. Decrease the current dosage of tacrolimusCevap
  2. B
    Increase the current dosage of tacrolimus
  3. C
    Initiate high-dose intravenous methylprednisolone
  4. D
    Initiate intravenous fluconazole therapy
  5. E
    Withhold antifungal therapy pending fungal blood culture results

Cevap

Decrease the current dosage of tacrolimus
This patient has a confirmed diagnosis of invasive pulmonary aspergillosis (IPA), indicated by the halo sign on CT and positive galactomannan. The standard-of-care targeted pharmacologic intervention is voriconazole. Voriconazole is a potent inhibitor of the cytochrome P450 3A4 (CYP3A4) isoenzyme. Tacrolimus, a calcineurin inhibitor crucial for preventing renal allograft rejection, has a narrow therapeutic index and is heavily metabolized by CYP3A4 in the liver and intestines. Concurrent initiation of voriconazole will dramatically reduce tacrolimus clearance, leading to toxic serum trough levels. This toxicity typically manifests as severe acute kidney injury (which is especially dangerous in a renal transplant recipient), hypertension, and neurologic complications such as seizures or posterior reversible encephalopathy syndrome (PRES). To safely manage this patient, the clinician must preemptively decrease the dosage of tacrolimus (often by 30% to 50%) when starting voriconazole and rigorously monitor serum trough levels.

Adım Adım Çözüm

1
Identify the primary diagnosis and the standard-of-care medication required.
The patient has invasive pulmonary aspergillosis (IPA). The first-line targeted pharmacologic therapy is intravenous voriconazole.
Establishing the specific antimicrobial required is necessary to evaluate its impact on the patient's complex baseline medication regimen.
2
Analyze the pharmacokinetic profile of the intended treatment against the patient's active medication list.
Voriconazole is a strong inhibitor of the hepatic cytochrome P450 3A4 (CYP3A4) enzyme system. The patient is taking tacrolimus, which is extensively metabolized by CYP3A4.
Identifying drug-drug interactions is critical in transplant patients to prevent organ rejection or drug toxicity.
3
Determine the necessary dosage adjustment based on the interaction.
Because voriconazole will inhibit the clearance of tacrolimus, the serum concentration of tacrolimus will rise significantly. The tacrolimus dose must be preemptively decreased (often by 1/3 to 1/2) and blood trough levels monitored closely.
Failure to reduce the dose will lead to acute calcineurin-inhibitor toxicity, manifesting as acute kidney injury, tremor, or seizures.

Anahtar Kavram

Initiation of voriconazole (a strong CYP3A4 inhibitor) for invasive aspergillosis requires a preemptive dose reduction of calcineurin inhibitors (like tacrolimus or cyclosporine) to prevent life-threatening drug toxicity.
Tahmini Süre:1m 30s
Bu soruyu puanla

Konular

Pharmacologic Interventions

Bu konudan daha fazla soru